US 9308256
Method of treating rheumatoid arthritis with an anti-IL-6R antibody
granted A61KA61K2039/505A61K31/4706
Quick answer
US patent 9308256 (Method of treating rheumatoid arthritis with an anti-IL-6R antibody) held by REGENERON PHARMACEUTICALS, INC. expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Apr 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K2039/505, A61K31/4706, A61K31/519, A61K31/655